KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $45.4 million.

  • GoodRx Holdings' Change in Accured Expenses rose 15522.61% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 22178.48%. This contributed to the annual value of $25.7 million for FY2024, which is 2096.65% up from last year.
  • Latest data reveals that GoodRx Holdings reported Change in Accured Expenses of $45.4 million as of Q3 2025, which was up 15522.61% from $15.8 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Change in Accured Expenses ranged from a high of $45.4 million in Q3 2025 and a low of -$19.1 million during Q1 2025
  • Moreover, its 5-year median value for Change in Accured Expenses was $5.9 million (2024), whereas its average is $5.2 million.
  • Per our database at Business Quant, GoodRx Holdings' Change in Accured Expenses plummeted by 410862.47% in 2022 and then soared by 141039.08% in 2025.
  • GoodRx Holdings' Change in Accured Expenses (Quarter) stood at $8.7 million in 2021, then crashed by 265.3% to -$14.4 million in 2022, then surged by 66.46% to -$4.8 million in 2023, then skyrocketed by 223.1% to $5.9 million in 2024, then soared by 666.19% to $45.4 million in 2025.
  • Its Change in Accured Expenses was $45.4 million in Q3 2025, compared to $15.8 million in Q2 2025 and -$19.1 million in Q1 2025.